Danaher Targets Faster Growth With Acquisitions, AI and a Diagnostics Push
Danaher (NYSE:DHR) has spent $11B on acquisitions this year, including Masimo and StatLab, expecting high-single-digit returns within five years. The company is also investing in AI and bioprocessing, with Cytiva targeted for long-term growth. Danaher plans opportunistic share buybacks and maintains its dividend commitment.


